MAPT and Alzheimer disease: In conclusion, the combination of GSK3β inhibition and Nrf2 induction in one molecule, described here for the first time, is aimed at decreasing tau hyperphosphorylation, to reduce oxidative stress and to diminish chronic neuroinflammation, that are major pathological hallmarks of AD.